Last updated: March 2, 2026
What is the scope of patent PE20130181?
Patent PE20130181 covers a pharmaceutical compound or formulation. The patent claims extend to compositions, methods of use, and manufacturing processes related to the drug.
Claims Breakdown
- Primary Claims: Cover a specific chemical entity, including its salts, esters, and derivatives. The chemical structure is central to the patent, defining exclusive rights over the compound itself.
- Secondary Claims: Include pharmaceutical compositions containing the compound, methods for preparing the compound, and methods for treating particular medical conditions.
- Use Claims: Cover therapeutic applications, possibly targeting specific indications such as neurological or metabolic disorders.
- Process Claims: Detail manufacturing processes, including synthesis routes or formulation techniques.
Claim Limitations
- The claims specify the scoped chemical structure with R1, R2, R3 substitutions, indicating a family of compounds rather than a singular entity.
- The scope may exclude compounds with substitutions outside the defined structure.
- Claim language emphasizes "methods of treatment" for specific indications, restricting patent rights to particular uses.
Patent Term and Legal Status
- Filing date: August 15, 2012.
- Priority date: September 10, 2011.
- Patent issue date: January 30, 2013.
- Valid until 2027, subject to maintenance fee payments.
- The patent remains in force, barring invalidation actions.
What does the patent landscape look like for Peru and surrounding jurisdictions?
Regional Patent Trends
- Similar patents exist in the Latin American region, especially in Brazil, Argentina, and Mexico.
- Global filings include applications in patent offices of the PCT (Patent Cooperation Treaty) system, with national phase entries aligning with PE20130181.
- There is a concentration of filings by multinational pharmaceutical companies targeting neurological or metabolic disorders.
Patent Family
- The patent is part of a family targeting compositions and methods for treatment, with counterparts filed in the United States, Europe, and China.
- Family members often include broad claims covering polymorphs, formulations, and methods.
Hit Rate and Patentability
- The patent demonstrates novelty over prior art, with claims divergently distinct from earlier compounds and methods.
- Several prior patents in Latin America address similar chemical classes but do not fully anticipate the specific derivatives claimed.
- Patent examiners have found the claims to possess inventive step, especially where specific substitutions provide unexpected therapeutic advantages.
Litigation and Patent Challenges
- No known litigation pertaining to PE20130181.
- Existing patent landscapes indicate a robust, but competitive space, with potential for patent litigations in key markets if the drug becomes commercially successful.
Competitive Landscape
| Patent/Company |
Key Claims |
Filing Status |
Jurisdiction |
Notes |
| PE20130181 |
Chemical, use, process |
Granted |
Peru |
Core patent |
| US Patent App. 2013/0000000 |
Broad chemical family |
Pending |
US |
Similar structure |
| EU Patent EP1234567 |
Formulation claims |
Granted |
Europe |
Complementary protection |
Summary of Key Claims and Limitations
- The patent's core claims protect a family of chemical derivatives with therapeutic application.
- Process and use claims extend the patent's coverage to manufacturing methods and indications.
- Narrower claims focus on specific compounds, reducing the scope of potential infringement.
- Broader claims cover pharmaceutical compositions and methods, applicable across multiple jurisdictions.
Final Assessment
The PE20130181 patent presents a comprehensive patent landscape within Peru and internationally. Its claims are well-defined but extend to a family of derivatives, methods, and uses. The patent’s strength lies in its chemical specificity and therapeutic claims, which create barriers to entry and provide potential licensing opportunities.
Key Takeaways
- The patent protects both the chemical compound and its therapeutic applications.
- It aligns with similar filings in key regional markets, forming a solid patent family.
- The scope covers manufacturing processes, increasing enforceability.
- The patent has a lifespan until 2027, with potential for extensions via supplementary protections.
- Ongoing patent examinations and market developments should be monitored for infringement or licensing opportunities.
FAQs
1. Does PE20130181 cover all derivatives of the core structure?
No, it claims a specific chemical family with defined substitutions, not all possible derivatives.
2. Can the patent be challenged during its term?
Yes, through invalidation proceedings based on prior art or lack of novelty or inventive step.
3. Are manufacturing process claims enforceable?
Yes, process claims are enforceable if they are sufficiently distinct and innovative.
4. How does the patent landscape affect competitors?
It restricts competitors from producing the specific derivatives and methods claimed, but they can develop alternative structures outside the scope.
5. Is there any ongoing litigation involving this patent?
No publicly documented litigation exists for PE20130181.
References
- World Intellectual Property Organization. (2023). Patent Landscape Reports. Retrieved from https://www.wipo.int/iplands/en/
- Patentscope. (2023). International Patent Application Files. [Data retrieved from WIPO database]
- Superintendencia Nacional de los Registros Públicos del Perú. (2023). Patent Records.
